1. Home
  2. BQ vs MBAI Comparison

BQ vs MBAI Comparison

Compare BQ & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

HOLD

Current Price

$0.97

Market Cap

7.7M

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

HOLD

Current Price

$8.07

Market Cap

8.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BQ
MBAI
Founded
2008
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.8M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
BQ
MBAI
Price
$0.97
$8.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.5M
73.6K
Earning Date
01-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$0.95
52 Week High
$72.74
$10.21

Technical Indicators

Market Signals
Indicator
BQ
MBAI
Relative Strength Index (RSI) 53.64 82.28
Support Level $0.70 $1.19
Resistance Level $1.41 $10.21
Average True Range (ATR) 0.18 0.44
MACD 0.01 0.63
Stochastic Oscillator 16.63 76.90

Price Performance

Historical Comparison
BQ
MBAI

About BQ Boqii Holding Limited representing

Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: